Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue

AY. Shuen, S. Lanni, GB. Panigrahi, M. Edwards, L. Yu, BB. Campbell, A. Mandel, C. Zhang, N. Zhukova, M. Alharbi, M. Bernstein, DC. Bowers, S. Carroll, KA. Cole, S. Constantini, B. Crooks, R. Dvir, R. Farah, N. Hijiya, B. George, TW. Laetsch, V....

. 2019 ; 37 (6) : 461-470. [pub] 20190104

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045066

Grantová podpora
CIHR - Canada

PURPOSE: Constitutional mismatch repair deficiency (CMMRD) is a highly penetrant cancer predisposition syndrome caused by biallelic mutations in mismatch repair (MMR) genes. As several cancer syndromes are clinically similar, accurate diagnosis is critical to cancer screening and treatment. As genetic diagnosis is confounded by 15 or more pseudogenes and variants of uncertain significance, a robust diagnostic assay is urgently needed. We sought to determine whether an assay that directly measures MMR activity could accurately diagnose CMMRD. PATIENTS AND METHODS: In vitro MMR activity was quantified using a 3'-nicked G-T mismatched DNA substrate, which requires MSH2-MSH6 and MLH1-PMS2 for repair. We quantified MMR activity from 20 Epstein-Barr virus-transformed lymphoblastoid cell lines from patients with confirmed CMMRD. We also tested 20 lymphoblastoid cell lines from patients who were suspected for CMMRD. We also characterized MMR activity from patients with neurofibromatosis type 1, Li-Fraumeni syndrome, polymerase proofreading-associated cancer syndrome, and Lynch syndrome. RESULTS: All CMMRD cell lines had low MMR activity (n = 20; mean, 4.14 ± 1.56%) relative to controls (n = 6; mean, 44.00 ± 8.65%; P < .001). Repair was restored by complementation with the missing protein, which confirmed MMR deficiency. All cases of patients with suspected CMMRD were accurately diagnosed. Individuals with Lynch syndrome (n = 28), neurofibromatosis type 1 (n = 5), Li-Fraumeni syndrome (n = 5), and polymerase proofreading-associated cancer syndrome (n = 3) had MMR activity that was comparable to controls. To accelerate testing, we measured MMR activity directly from fresh lymphocytes, which yielded results in 8 days. CONCLUSION: On the basis of the current data set, the in vitro G-T repair assay was able to diagnose CMMRD with 100% specificity and sensitivity. Rapid diagnosis before surgery in non-neoplastic tissues could speed proper therapeutic management.

Aga Khan University Hospital Karachi Pakistan

Ann and Robert H Lurie Children's Hospital Northwestern University Feinberg School of Medicine Chicago IL

Banner MD Anderson Cancer Center Gilbert AZ

Baylor College of Medicine and Texas Children's Hospital Houston TX 27 Universidad San Francisco de Quito Quito Ecuador

Children Cancer Hospital Karachi Pakistan

Children's Hospital Colorado Aurora CO 31 University of Colorado Anschutz Medical Campus Aurora CO

Children's Hospital of Philadelphia and University of Pennsylvania Philadelphia PA

Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center Pittsburgh PA

Cleveland Clinic Weston FL

Dalhousie University Faculty of Medicine Halifax Nova Scotia Canada

Geisinger Medical Center Danville PA

King Fahad Medical City Riyadh Saudi Arabia

McGill University Health Centre Montréal Quebec Canada

McGill University Montréal Quebec Canada

Medical College of Wisconsin Milwaukee WI

Medical University of South Carolina Charleston SC

Mount Sinai Hospital Toronto Ontario Canada

Mount Sinai Hospital Toronto Ontario Canada 38 Toronto General Hospital Toronto Ontario Canada

Ottawa Hospital Research Institute Ottawa Ontario Canada

Rambam Health Care Campus Haifa Israel

Ruby Memorial Hospital Morgantown WV

Saint George Hospital University Medical Center Beirut Lebanon

Schneider Children's Medical Center of Israel Petach Tikva Israel

Sheba Medical Center Tel Hashomer Israel

Taipei Veterans General Hospital Taipei Republic of China

Tel Aviv Sourasky Medical Center Tel Aviv Israel 10 Tel Aviv University Tel Aviv Israel

Tel Aviv University Tel Aviv Israel 11 Schneider Children's Medical Center of Israel Petach Tikva Israel

The Hospital for Sick Children Toronto Ontario Canada

The Hospital for Sick Children Toronto Ontario Canada 32 Mount Sinai Hospital Toronto Ontario Canada

Université Catholique de Louvain Brussels Belgium

Université Laval Quebec City Quebec Canada

University Hospital Motol Charles University Prague Czech Republic

University of Colorado Anschutz Medical Campus Aurora CO

University of Manitoba Winnipeg Manitoba Canada

University of Texas Southwestern Medical Center Dallas TX 6 Children's Health Dallas TX

University of Toronto Toronto Ontario Canada 2 The Hospital for Sick Children Toronto Ontario Canada

University of Toronto Toronto Ontario Canada 2 The Hospital for Sick Children Toronto Ontario Canada 34 University Hospital Motol Charles University Prague Czech Republic

University of Toronto Toronto Ontario Canada 20 Princess Margaret Cancer Centre Toronto Ontario Canada

Valley Children's Hospital Madera CA

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045066
003      
CZ-PrNML
005      
20200115082737.0
007      
ta
008      
200109s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.18.00474 $2 doi
035    __
$a (PubMed)30608896
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Shuen, Andrew Y $u 1 University of Toronto, Toronto, Ontario, Canada. 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
245    10
$a Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue / $c AY. Shuen, S. Lanni, GB. Panigrahi, M. Edwards, L. Yu, BB. Campbell, A. Mandel, C. Zhang, N. Zhukova, M. Alharbi, M. Bernstein, DC. Bowers, S. Carroll, KA. Cole, S. Constantini, B. Crooks, R. Dvir, R. Farah, N. Hijiya, B. George, TW. Laetsch, V. Larouche, S. Lindhorst, RC. Luiten, V. Magimairajan, G. Mason, W. Mason, O. Mordechai, N. Mushtaq, G. Nicholas, M. Oren, L. Palma, LA. Pedroza, J. Ramdas, D. Samuel, K. Wolfe Schneider, A. Seeley, K. Semotiuk, A. Shamvil, D. Sumerauer, H. Toledano, P. Tomboc, M. Wierman, A. Van Damme, YY. Lee, M. Zapotocky, E. Bouffet, C. Durno, M. Aronson, S. Gallinger, WD. Foulkes, D. Malkin, U. Tabori, CE. Pearson,
520    9_
$a PURPOSE: Constitutional mismatch repair deficiency (CMMRD) is a highly penetrant cancer predisposition syndrome caused by biallelic mutations in mismatch repair (MMR) genes. As several cancer syndromes are clinically similar, accurate diagnosis is critical to cancer screening and treatment. As genetic diagnosis is confounded by 15 or more pseudogenes and variants of uncertain significance, a robust diagnostic assay is urgently needed. We sought to determine whether an assay that directly measures MMR activity could accurately diagnose CMMRD. PATIENTS AND METHODS: In vitro MMR activity was quantified using a 3'-nicked G-T mismatched DNA substrate, which requires MSH2-MSH6 and MLH1-PMS2 for repair. We quantified MMR activity from 20 Epstein-Barr virus-transformed lymphoblastoid cell lines from patients with confirmed CMMRD. We also tested 20 lymphoblastoid cell lines from patients who were suspected for CMMRD. We also characterized MMR activity from patients with neurofibromatosis type 1, Li-Fraumeni syndrome, polymerase proofreading-associated cancer syndrome, and Lynch syndrome. RESULTS: All CMMRD cell lines had low MMR activity (n = 20; mean, 4.14 ± 1.56%) relative to controls (n = 6; mean, 44.00 ± 8.65%; P < .001). Repair was restored by complementation with the missing protein, which confirmed MMR deficiency. All cases of patients with suspected CMMRD were accurately diagnosed. Individuals with Lynch syndrome (n = 28), neurofibromatosis type 1 (n = 5), Li-Fraumeni syndrome (n = 5), and polymerase proofreading-associated cancer syndrome (n = 3) had MMR activity that was comparable to controls. To accelerate testing, we measured MMR activity directly from fresh lymphocytes, which yielded results in 8 days. CONCLUSION: On the basis of the current data set, the in vitro G-T repair assay was able to diagnose CMMRD with 100% specificity and sensitivity. Rapid diagnosis before surgery in non-neoplastic tissues could speed proper therapeutic management.
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a nádory mozku $x diagnóza $x genetika $x metabolismus $7 D001932
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a kolorektální nádory $x diagnóza $x genetika $x metabolismus $7 D015179
650    12
$a oprava chybného párování bází DNA $7 D053843
650    _2
$a enzymy opravy DNA $x genetika $x metabolismus $7 D045643
650    _2
$a DNA vazebné proteiny $x genetika $x metabolismus $7 D004268
650    _2
$a genetická predispozice k nemoci $7 D020022
650    12
$a genetické testování $7 D005820
650    _2
$a lidé $7 D006801
650    _2
$a mismatch repair endonukleáza PMS2 $x genetika $x metabolismus $7 D000070976
650    _2
$a MutL homolog 1 $x genetika $x metabolismus $7 D000070957
650    _2
$a homolog 2 proteinu MutS $x genetika $x metabolismus $7 D051718
650    12
$a mutace $7 D009154
650    _2
$a dědičné nádorové syndromy $x diagnóza $x genetika $x metabolismus $7 D009386
650    _2
$a fenotyp $7 D010641
650    _2
$a prediktivní hodnota testů $7 D011237
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lanni, Stella $u 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Panigrahi, Gagan B $u 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Edwards, Melissa $u 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Yu, Lisa $u 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Campbell, Brittany B $u 1 University of Toronto, Toronto, Ontario, Canada. 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Mandel, Ariane $u 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Zhang, Cindy $u 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Zhukova, Nataliya $u 1 University of Toronto, Toronto, Ontario, Canada. 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Alharbi, Musa $u 3 King Fahad Medical City, Riyadh, Saudi Arabia.
700    1_
$a Bernstein, Mark $u 4 Dalhousie University Faculty of Medicine, Halifax, Nova Scotia, Canada.
700    1_
$a Bowers, Daniel C $u 5 University of Texas Southwestern Medical Center, Dallas, TX. 6 Children's Health, Dallas, TX.
700    1_
$a Carroll, Sara $u 7 Cleveland Clinic, Weston FL.
700    1_
$a Cole, Kristina A $u 8 Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA.
700    1_
$a Constantini, Shlomi $u 9 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 10 Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Crooks, Bruce $u 4 Dalhousie University Faculty of Medicine, Halifax, Nova Scotia, Canada.
700    1_
$a Dvir, Rina $u 10 Tel Aviv University, Tel Aviv, Israel. 11 Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
700    1_
$a Farah, Roula $u 12 Saint George Hospital University Medical Center, Beirut, Lebanon.
700    1_
$a Hijiya, Nobuko $u 13 Ann & Robert H. Lurie Children's Hospital/Northwestern University Feinberg School of Medicine, Chicago, IL.
700    1_
$a George, Ben $u 14 Medical College of Wisconsin, Milwaukee, WI.
700    1_
$a Laetsch, Theodore W $u 5 University of Texas Southwestern Medical Center, Dallas, TX. 6 Children's Health, Dallas, TX.
700    1_
$a Larouche, Valerie $u 15 Université Laval, Quebec City, Quebec, Canada.
700    1_
$a Lindhorst, Scott $u 16 Medical University of South Carolina, Charleston, SC.
700    1_
$a Luiten, Rebecca C $u 17 Banner MD Anderson Cancer Center, Gilbert, AZ.
700    1_
$a Magimairajan, Vanan $u 18 University of Manitoba, Winnipeg, Manitoba, Canada.
700    1_
$a Mason, Gary $u 19 Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA.
700    1_
$a Mason, Warren $u 1 University of Toronto, Toronto, Ontario, Canada. 20 Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
700    1_
$a Mordechai, Oz $u 21 Rambam Health Care Campus, Haifa, Israel.
700    1_
$a Mushtaq, Naureen $u 22 Aga Khan University Hospital, Karachi, Pakistan.
700    1_
$a Nicholas, Garth $u 23 Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
700    1_
$a Oren, Michael $u 24 Sheba Medical Center, Tel Hashomer, Israel.
700    1_
$a Palma, Laura $u 25 McGill University Health Centre, Montréal, Quebec, Canada.
700    1_
$a Pedroza, Luis Alberto $u 26 Baylor College of Medicine and Texas Children's Hospital, Houston, TX. 27 Universidad San Francisco de Quito, Quito, Ecuador.
700    1_
$a Ramdas, Jagadeesh $u 28 Geisinger Medical Center, Danville, PA.
700    1_
$a Samuel, David $u 29 Valley Children's Hospital, Madera, CA.
700    1_
$a Wolfe Schneider, Kami $u 30 Children's Hospital Colorado, Aurora, CO. 31 University of Colorado, Anschutz Medical Campus, Aurora, CO.
700    1_
$a Seeley, Andrea $u 28 Geisinger Medical Center, Danville, PA.
700    1_
$a Semotiuk, Kara $u 32 Mount Sinai Hospital, Toronto, Ontario, Canada.
700    1_
$a Shamvil, Ashraf $u 33 Children Cancer Hospital, Karachi, Pakistan.
700    1_
$a Sumerauer, David $u 34 University Hospital Motol, Charles University, Prague, Czech Republic.
700    1_
$a Toledano, Helen $u 11 Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
700    1_
$a Tomboc, Patrick $u 35 Ruby Memorial Hospital, Morgantown, WV.
700    1_
$a Wierman, Margaret $u 31 University of Colorado, Anschutz Medical Campus, Aurora, CO.
700    1_
$a Van Damme, An $u 36 Université Catholique de Louvain, Brussels, Belgium.
700    1_
$a Lee, Yi-Yen $u 37 Taipei Veterans General Hospital, Taipei, Republic of China.
700    1_
$a Zapotocky, Michal $u 1 University of Toronto, Toronto, Ontario, Canada. 2 The Hospital for Sick Children, Toronto, Ontario, Canada. 34 University Hospital Motol, Charles University, Prague, Czech Republic.
700    1_
$a Bouffet, Eric $u 1 University of Toronto, Toronto, Ontario, Canada. 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Durno, Carol $u 2 The Hospital for Sick Children, Toronto, Ontario, Canada. 32 Mount Sinai Hospital, Toronto, Ontario, Canada.
700    1_
$a Aronson, Melyssa $u 32 Mount Sinai Hospital, Toronto, Ontario, Canada.
700    1_
$a Gallinger, Steve $u 32 Mount Sinai Hospital, Toronto, Ontario, Canada. 38 Toronto General Hospital, Toronto, Ontario, Canada.
700    1_
$a Foulkes, William D $u 39 McGill University, Montréal, Quebec, Canada.
700    1_
$a Malkin, David $u 1 University of Toronto, Toronto, Ontario, Canada. 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Tabori, Uri $u 1 University of Toronto, Toronto, Ontario, Canada. 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
700    1_
$a Pearson, Christopher E $u 1 University of Toronto, Toronto, Ontario, Canada. 2 The Hospital for Sick Children, Toronto, Ontario, Canada.
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 37, č. 6 (2019), s. 461-470
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30608896 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200115083110 $b ABA008
999    __
$a ok $b bmc $g 1483335 $s 1083739
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 37 $c 6 $d 461-470 $e 20190104 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
GRA    __
$p CIHR $2 Canada
LZP    __
$a Pubmed-20200109
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace